Cell Death and Disease (Oct 2021)

Lnc-PFAR facilitates autophagy and exacerbates pancreatic fibrosis by reducing pre-miR-141 maturation in chronic pancreatitis

  • Tao Zhang,
  • Guangquan Zhang,
  • Wenbo Yang,
  • Hongze Chen,
  • Jisheng Hu,
  • Zhongjie Zhao,
  • Chundong Cheng,
  • Guanqun Li,
  • Yu Xie,
  • Yilong Li,
  • Rui Kong,
  • Yongwei Wang,
  • Gang Wang,
  • Hua Chen,
  • Xue-Wei Bai,
  • Shangha Pan,
  • Bei Sun,
  • Le Li

DOI
https://doi.org/10.1038/s41419-021-04236-z
Journal volume & issue
Vol. 12, no. 11
pp. 1 – 11

Abstract

Read online

Abstract Chronic pancreatitis (CP) is described as progressive inflammatory fibrosis of pancreas, accompanied with irreversible impaired endocrine and exocrine insufficiency. Pancreatic stellate cells (PSCs) are widely distributed in the stroma of the pancreas and PSCs activation has been shown as one of the leading causes for pancreatic fibrosis. Our previous study has revealed that autophagy is dramatically activated in CP tissues, which facilitates PSCs activation and pancreatic fibrosis. Long non-coding RNAs (LncRNAs) have been recognized as crucial regulators for fibrosis-related diseases. LncRNAs interact with RNA binding protein or construct competitive endogenous RNA (ceRNA) hypothesis which elicited the fibrotic processes. Until now, the effects of lncRNAs on PSCs activation and pancreatic fibrosis have not been clearly explored. In this study, a novel lncRNA named Lnc-PFAR was found highly expressed in mouse and human CP tissues. Our data revealed that Lnc-PFAR facilitates PSCs activation and pancreatic fibrosis via RB1CC1-induced autophagy. Lnc-PFAR reduces miR-141 expression by suppressing pre-miR-141 maturation, which eventually upregulates the RB1CC1 and fibrosis-related indicators expression. Meanwhile, Lnc-PFAR enhanced PSCs activation and pancreatic fibrosis through trigging autophagy. Our study interrogates a novel lncRNA-induced mechanism in promoting the development of pancreatic fibrosis, and Lnc-PFAR is suggested to be a prospective therapeutic target in clinical scenarios.